Telaprevir versus simeprevir for the treatment of recurrent hepatitis C after living donor liver transplantation

Hepatology Research

Volumn 46, Issue 3, 2016, Pages E136-E145

  Ikegami, Toru ^a   Yoshizumi, Tomoharu ^a   Yoshida, Yoshihro ^a   Kurihara, Takeshi ^a   Harimoto, Norifumi ^a   Itoh, Shinji ^a   Shimokawa, Masahiro ^a   Fukuhara, Takasuke ^a   Shirabe, Ken ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Hepatitis C; Interferon; Liver transplantation; Living donor; Simeprevir; Telaprevir

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PEGINTERFERON ALPHA2B; PREDNISOLONE; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT DURATION; VIRAL CLEARANCE;

EID: 84935445760     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12546     Document Type: Article

References (26)

1. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-8.
2. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
3. Teixeira R, Menezes EG, Schiano TD. Therapeutic management of recurrent hepatitis C after liver transplantation. Liver Int 2007; 27: 302-12.
4. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
5. Ikegami T, Yoshizumi T, Kato M, etal. Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Transplantation 2014; 98: 994-9.
6. Tanaka T, Sugawara Y, Akamatsu N etal. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci 2014. doi: 10.1002/jhbp.171. [Epub ahead of print]
7. Ueda Y1, Kaido T, Uemoto S. Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation. Transpl Int 2014. doi: 10.1111/tri.12438. [Epub ahead of print]
8. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
9. Hafez T. Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration rate (eGFR) formula. Am J Cardiol 2007; 99: 584.
10. Ikegami T, Shirabe K, Yamashita Y, etal. Small upper midline incision for living donor hemi-liver graft procurement in adults. J Am Coll Surg 2014; 219(3): e39-43.
11. Ikegami T, Soejima Y, Taketomi A, etal. Explanted portal vein grafts for middle hepatic vein tributaries in living-donor liver transplantation. Transplantation 2007; 84(7): 836-41.
12. Ikegami T, Shirabe K, Soejima Y, etal. Strategies for successful left-lobe living donor liver transplantation in 250 consecutive adult cases in a single center. J Am Coll Surg 2013; 216(3): 353-62.
13. Fukuhara T, Taketomi A, Motomura T, etal. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-85.
14. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-17.
15. Fiel MI, Agarwal K, Stanca C, etal. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008; 14: 861-71.
16. Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl 2008; 14: 625-32.
17. Pungpapong S, Aqel BA, Koning L, etal. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
18. Coilly A, Roche B, Dumortier J, etal. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
19. Hayashi N, Izumi N, Kumada H, etal. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 61(2): 219-27.
20. McPhee F, Hernandez D, Yu F, etal. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013; 58: 902-11.
21. Reesink HW, Fanning GC, Farha KA, etal. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-21.
22. Bae A, Sun SC, Qi X, etal. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 2010 54: 5288-97.
23. Sebagh M, Azoulay D, Roche B, etal. Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation. Liver Transpl 2011; 17: 798-808.
24. Hübscher SG. Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transpl 2008; 14: 596-600.
25. Merli M, Gentili F, Giusto M, etal. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 2009; 41: 345-9.
26. Levitsky J, Fiel MI, Norvell JP, etal. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132-9.